Amalgamated Financial’s Rubius Therapeutics, Inc RUBY Stock Holding History

Amalgamated Financial’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$41K	Buy	+7,502	New	+$47.6K	﹤0.01%	2515

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Abbot Financial Management Andover, Massachusetts $293M AUM 36.12% 1-Year Est. Return

Amalgamated Financial's RUBY Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Rubius Therapeutics, Inc (RUBY) in Q1 2022: 7,502 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #2515 among its holdings.

117 funds tracked by Wall St. Rank hold RUBY as of Q1 2022.

Amalgamated Financial held 7,502 shares of Rubius Therapeutics, Inc worth $41K as of Q1 2022.
Rubius Therapeutics, Inc was a new Amalgamated Financial position in Q1 2022.
Rubius Therapeutics, Inc made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2515 holding.
117 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.